CAS: 496775-62-3; 2-Aminoethan-1-Ol Hemi((Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-Methyl-5-Oxo-1,5-Dihydro-4H-Pyrazol-4-Ylidene)Hydrazinyl)-2'-Hydroxy-[1,1'-Biphenyl]-3-Carboxylate)

专利信息

专利号:WO-2013049605-A1
优先权日:2011-09-28
标题 :Processes for the preparation of an intermediate in the synthesis of eltrombopag
发明人：AVDAGIC AMIR; BARAN PHIL S
权利人:ASSIA CHEM IND LTD; TEVA PHARMACEUTICAL USA INC
摘要:3'-Amino-2'-hydroxybiphenyl-3-carboxylic acid (BPCA) and related compounds have been prepared using compounds such as: wherein R 1 is -H, -Cl or -F; R 2 is -Br or -I; and R 3 is -H or -N0 2 . BPCA is useful, for example, in the preparation of Eltrombopag.

专利号:US-2018140724-A1
优先权日:2015-05-27
标 题:Tumor Deliverable Iron and Protein Synthesis Inhibitors as a New Class of Drugs for the Diagnosis and Treatment of Cancer
发明人：DENG CHANGCHUN; LIPSTEIN MARK; O'CONNOR OWEN A
权利人:DENG CHANGCHUN; LIPSTEIN MARK; OCONNOR OWEN A; UNIV COLUMBIA
摘要:Tumor deliverable iron (TDI) drugs and pharmaceutical compositions and kits comprising them are provided and methods for delivering iron to tumors specifically, either intracellularly or extracellularly. As a result, TDI drugs are useful as a sensitizer for radiation therapy, radio-diagnosis, and chemotherapy, and are of interest. In other embodiments, tumor deliverable protein synthesis inhibitors (TDPSI) are provided and can be delivered to tumors, but not normal cells. These TDPSI drugs and pharmaceutical compositions and kits comprising them are useful for their treatment of cancer, either alone or in combination with other active anti-cancer drugs.

专利号:CN-114072386-A
优先权日:2019-07-04
标题 :Improved process for the preparation of key intermediates for the synthesis of eltrombopag or salts thereof

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.

专利号:CN-116514661-B
优先权日:2023-06-30
标 题 :Continuous flow synthesis method of 4-bromo-2-nitrophenol

专利号:CN-116514661-A
优先权日:2023-06-30
标题:Continuous flow synthesis method of 4-bromo-2-nitrophenol